

UC Irvine

UC Irvine Previously Published Works

Title

Synthesis, molecular modeling, and biological evaluation of novel RAD51 inhibitors

Permalink

<https://escholarship.org/uc/item/8fm7s926>

Authors

Zhu, Jiewen
Chen, Hongyuan
Guo, Xuning Emily
[et al.](#)

Publication Date

2015-05-01

DOI

10.1016/j.ejmech.2015.04.021

Peer reviewed



Published in final edited form as:

Eur J Med Chem. 2015 May 26; 96: 196–208. doi:10.1016/j.ejmech.2015.04.021.

Synthesis, Molecular Modeling, and Biological Evaluation of Novel RAD51 Inhibitors

Jiewen Zhu^{†,§}, Hongyuan Chen^{†,§}, Xuning Emily Guo^{†,§}, Xiao-Long Qiu[†], Chun-Mei Hu^{†,&}, A. Richard Chamberlin[‡], and Wen-Hwa Lee^{†,#,*}

[†]Department of Biological Chemistry, School of Medicine, University of California, Irvine, Irvine, CA 92697, USA

[‡]Department of Pharmaceutical Sciences, University of California, Irvine, Irvine, CA 92697, USA

[#]Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan

Abstract

RAD51 recombinase plays a critical role for cancer cell proliferation and survival. Targeting RAD51 is therefore an attractive strategy for treating difficult-to-treat cancers, e.g. triple negative breast cancers which are often resistant to existing therapeutics. To this end, we have designed, synthesized and evaluated a panel of new RAD51 inhibitors, denoted IBR compounds. Among these compounds, we have identified a novel small molecule RAD51 inhibitor, **IBR120**, which exhibited a 4.8-fold improved growth inhibition activity in triple negative human breast cancer cell line MBA-MD-468. **IBR120** also inhibited the proliferation of a broad spectrum of other cancer cell types. Approximately 10-fold difference between the IC₅₀ values in normal and cancer cells were observed. Moreover, **IBR120** was capable of disrupting RAD51 multimerization, impairing homologous recombination repair, and inducing apoptotic cell death. Therefore, these novel RAD51 inhibitors may serve as potential candidates for the development of pharmaceutical strategies against difficult-to-treat cancers.

Keywords

RAD51 inhibitor; indole alkaloid; breast cancer; triple-negative; QSAR; synthesis

© 2015 Published by Elsevier Masson SAS.

*To whom correspondence should be addressed. Address: Wen-Hwa Lee, Department of Biological Chemistry, School of Medicine, University of California, Irvine, 240 Med Sci D, Irvine, CA 92697. Phone: (949)-824-8858. Fax: (949)-824-9767. whlee@uci.edu. Current addresses: [#] Graduate Institute of Clinical Medical Science, China Medical University, Taichung; [&] Taiwan Genomic Research Center, Academia Sinica, Taipei, Taiwan.

[§]These authors contributed equally to this work.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Author contributions:

HC, XLQ, and JZ designed, synthesized, and characterized all compounds under the guidance of ARC; XEG and CMH performed XTT assay and HR assay; JZ performed the gel filtration assay, QSAR analysis, and molecular modeling. JZ and WHL wrote the paper with inputs from all authors.

1. Introduction

Targeting DNA damage repair pathway as a novel means of treating cancer, especially difficult-to-treat cancers, has attracted much attention in the past few years. Homologous recombination (HR) is one of the most prominent repair pathways and is required for cancer cells to undergo continuous proliferation under stress. Therefore, various efforts have been taken to inhibit or modulate this pathway, in the hope of rendering cancer cells vulnerable [1–4]. As one of the key players in HR, RAD51 is essential for DNA repair, proliferation and survival. RAD51 protein level is elevated in many cancer cells, contributing to their resistance to chemotherapy and the continuous cell proliferation [5–14]. Therefore, RAD51 inhibition has been pursued by several groups in search of a novel potential treatment for difficult-to-treat-cancers [2, 3, 15].

Recently, our group identified and validated a small molecule synthetic alkaloid, named **IBR2** (Figure 1), which showed interesting RAD51 inhibition activities both in vitro and in vivo [15]. RAD51 was rapidly degraded in **IBR2**-treated cancer cells, and the homologous recombination repair was impaired, subsequently leading to cell death. Therefore, **IBR2** represents a novel class of direct and specific RAD51 inhibitors [1–3, 15]. The IC₅₀ values of the original **IBR2** were in the range of 12–20 μM for most tested cancer cell lines. Its molecular scaffold contains a chiral center and the structure-activity relationship of this chirality has not been explored in our previous studies. It is well accepted that the interaction between chiral molecules and biological systems can provide more mechanistic insight and important clues for drug discovery and development [16]. Therefore, we sought to develop efficient and stereo-selective synthetic routes such that more potent analogues can be identified [17]. In this report, several types of **IBR2** analogues **IBR101–124** were designed, synthesized, modeled, and biologically evaluated. These new compounds constitute a focused compound library representing a diversity of modified scaffold or substituents (Figure 1). As a result, a 4.8-fold improved RAD51 inhibitor was identified, which was able to inhibit the growth of triple-negative breast cancer cells and a panel of other malignancies. This finding may provide support for innovative methods and developments in cancer treatment.

2. Results and Discussion

2.1 Synthesis of IBR2 analogues

1,2,3,4-tetrahydroisoquinoline indole alkaloids **IBR101–114** were stereoselectively synthesized by the addition of *N*-Boc-3-bromo-indole **1** to the chiral benzylidene sulfonamide **2** as key steps [17]. 2,3-dihydro-1*H*-benzo[*c*]azepine analogues **IBR115–116** were stereoselectively synthesized using the bifunctional cinchona alkaloid-thiourea catalyzed addition of unprotected indole **3** to the sulfonyl amide **4** (Scheme 1) [17, 18].

Synthesis of optically pure indazole derivative **IBR117** embarked on the reaction of the chiral benzylidene sulfonamide **2** [17] and 3-Bromoindazole **5**. The desired indazolylated adduct **6** was obtained in medium yield (43%) and diastereoselectivity (65% *dr*) (Scheme 2) [19]. Protection of **6** with Boc₂O gave compounds **7** and **8** in 66% and 14% yields, respectively. To our delight, the diastereoisomers **7** and **8** could be readily separated by

silica gel column chromatography. Then, starting with chiral sulfinamide **8**, HCl-mediated removal of the *tert*-butanesulfinyl group provided the amine product **9** in 90% yield. Subjecting the amine **9** to Pd/C-catalyzed hydrogenation followed by exposure of the resultant alcohol to CbzCl/DIPEA gave the compound **10** in 61% yield over 2 steps. Alcohol **10** was further mesylated to give compound **11** in 91% yield. Once hydrogenation of the mesylate **11** was carried out with Pd/C as catalyst in MeOH, the desired cyclic amine **12** was isolated in 94% yield, which led directly to **IBR117** in 61% yield via deprotection with NaOMe/MeOH and subsequent benzylsulfonylation. Utilizing similar reaction procedures, the *S* configuration indazole derivative **IBR118** was also prepared starting from chiral sulfinamide **7** in 37% yield over 5 steps (Scheme 3).

Chiral thiazolylamine derivative **IBR119** was synthesized starting from *N*-Boc-2-amino-5-bromothiazole **17** and chiral benzylidene sulfinamide **2** (Scheme 4). Addition proceeded well by treatment of compound **2** with *N*-Boc-2-amino-5-lithiothiazole (prepared *in situ* via reaction of **17** with *n*-BuLi) at -78 °C, and the desired sulfinamides **18** and **19** were provided in 39% yield with medium diastereoselectivity (59% *dr*). Diastereoisomers **18** and **19** (1:4 isolated molar ratio) were then successfully separated through silica gel chromatography (isolated yield: 8% and 31%, respectively). The major diastereomer compound **19** was chosen for further modification. *tert*-Butanesulfinyl group of **19** was removed by treatment with 4M HCl in dioxane and the amine **20** was obtained in almost quantitative yield. Benzylsulfonylation of **20** gave compound **21** in 97% yield, which was subjected to Pd/C-catalyzed hydrogenation to afford the alcohol **22** in 80% yield. Mesylation of **22** by treatment with MsCl/DMAP/DIPEA followed by exposure of resultant mesylate to KHDMS in THF furnished the desired cyclic compound **23**. Synthesis of **IBR119** was finally accomplished via TFA-mediated removal of Boc protecting group in **23**.

Synthesis of isoindolyl derivative **IBR120** started from the indole-derived compound **24**, which was prepared according to our previous report [17, 18]. A direct OsO₄-NaIO₄ mediated oxidative cleavage reaction on unprotected compound **24** in the presence of 2, 6-lutidine [20] was carried out, followed by reduction with NaBH₄ and resulted in alcohol **25** (82%). Alcohol **25** was then treated with mesyl chloride and an appropriate base in DCM to give the corresponding mesylate, which was used as an intermediate for the following cyclisation reaction to form **IBR120**. Our first attempt on cyclization of alcohol **25** using KHMDS as a base in THF gave a racemic product. Reaction conditions with milder bases were then investigated (Table S1 in Supporting Information). Reactions with Et₃N in DCM at r.t. or in dioxane under reflux did not facilitate the conversion. The use of K₂CO₃ in MeOH gave racemic cyclization product in 42 % yield. Finally, with Hünig's base in acetonitrile, the desired product **IBR120** was obtained in 53 % yield with > 95% ee (Scheme 5). Utilizing the similar reaction procedures, the *S* configuration isomer **IBR121** was also prepared starting from the indole-derived compound **26** (Scheme 6). Chiral HPLC analysis confirmed high enantiomeric purities of **IBR120** and **IBR121** (See Figure S1-S3 in Supporting Information for representative HPLC profiles).

To explore possible effects of other indole bioisosteres on the bioactivity, racemic azaindole derivatives **IBR122–124** were synthesized using a facile one-pot synthetic method as

described in our previous report [15], starting from azaindoles **27**, **28**, and **29**, respectively (Scheme 7).

2.2 IBR2 Analogues Inhibit Growth of Triple-Negative Human Breast Cancer

Triple-negative breast cancer is often easy to metastasize and difficult to treat using existing therapeutics [21, 22]. As a broad spectrum anti-cancer agent, **IBR2** was able to inhibit a number of difficult-to-treat cancers [15]. To test the possibility of inhibiting triple-negative breast cancer, we screened the newly synthesized **IBR2** analogues **IBR101–124** of their growth inhibition abilities using an XTT assay. As shown in Table 1, most of these synthetic **IBR2** analogues can inhibit the growth of triple-negative human breast cancer cell line MBA-MD-468.

We found that the half inhibitory concentrations (IC_{50}) of 1,2,3,4-tetrahydroisoquinoline analogues **IBR101**, **102**, **103**, **105**, **107**, **109**, **111**, **113**, **118**, 2,3-dihydro-1*H*-benzo[*c*]azepine analogue **IBR115**, and 1,2-dihydroisoquinoline analogue **IBR122** were slightly lower than that of the parental compound **IBR2**; while 1,2,3,4-tetrahydroisoquinoline analogue **IBR117**, isoindoline analogue **IBR120**, and 1,2-dihydroisoquinoline analogues **IBR123**, **124** were significantly lower than that of **IBR2**. In all the successfully synthesized enantiomers, the *R* configuration consistently exhibited better bioactivity than the *S* configuration. Among all these analogues, **IBR120** exhibited a 4.8-fold increase in activity ($IC_{50} = 3.1 \mu\text{M}$), followed by **IBR124**, **123** and **117**, with 1.6~2.4-fold increase in activities ($IC_{50} = 6.2, 6.3, 9.5 \mu\text{M}$, respectively), compared to the parental compound **IBR2** ($IC_{50} = 14.8 \mu\text{M}$).

2.3 IBR120 inhibits a panel of cancer cell lines growth

We then tested the best analogue **IBR120** on the growth inhibition of a panel of cancer cell lines using XTT assay. These cell lines included human Chronic Myelogenous Leukemia cell line K562, human breast cancer cell lines MCF7, MDA-MB-231, MDA-MB-361, MDA-MB-435, MDA-MB-468, Hs578-T, and T47D, human Osteosarcoma cell line U2OS, human Glioblastoma cell line T98G, human Cervical Cancer cell line HeLa, as well as human mammary gland normal epithelial cell line MCF10A (normal control). As shown in Table 2, while essentially nontoxic to the normal cell line MCF10A ($IC_{50} > 30 \mu\text{M}$), **IBR120** exhibited killing effect in most tested cancer cell lines with IC_{50} values in low micromolar range (3~5 μM). This approximately 10-fold difference between the IC_{50} values in normal and cancer cells demonstrates a potential therapeutic window for future drug development.

2.4 Molecular Docking Model

We have previously shown that the phenylalanine binding site on the RAD51 core domain was responsible for **IBR2** binding [15]. Blocking of this site inhibits RAD51 multimerization and leads to deficiencies in DNA repair; while mutation in the center of this site abolishes the binding [15]. ICM software was employed to prepare the structures of RAD51 core domain, and to perform the molecular docking studies with **IBR2** analogues. The crystal structure of human RAD51 in complex with BRC4 peptide (PDB No. 1N0W) [24] was chosen for molecular docking studies. Initially a docking box containing all the

atoms of RAD51 residues within 5 Å distance from the BRC4 peptide in 1N0W was used; and a “blind docking” procedure was performed using **IBR2** as probe. Then the docking box was fixed and used for all docking studies with **IBR2** analogues; the amino acid residues within the box contain RAD51 residues M158, Y159, I160, F167, P168, L171, S183, V185, L186, D187, N188, V189, A190, Y191, A192, R193, A194, F195, H199, Q202, L203, L204, Y205, Q206, A207, S208, A209, M210, V212, E213, Y216, L219, R247, R250, M251, L252, R254, L255, E258, F259. Molecular docking was then performed following rigid docking protocols; docking scores were collected and conformational analysis was performed based on the results.

Many of the residues in the binding site are hydrophobic and therefore provides hydrophobic surface for interacting with the aromatic ring systems of the IBR compounds. Three potential hydrogen bonding sites were identified between **IBR120** and RAD51 residues V189, Y191, and Q206. The distance between the indole nitrogen atom and the backbone carbonyl oxygen of V189 was 3.3 Å, suggesting a hydrogen bond of moderate strength may be involved in the binding. This notion is partly consistent with our previous finding that methylation of the indolyl nitrogen resulted in loss of activity [15]. An alternative explanation for the loss of activity in the N-methylated analogue could be that the methyl group might introduce unfavorable steric interaction with the corresponding amino acid residues on RAD51. Moreover, both of the sulfonyl oxygen atoms seem to be involved in weak hydrogen bonding, which could explain the observed loss of function when changing the sulphonyl into carbonyl group as our previous results showed [15] (Figure 2).

2.5 Quantitative Structure Activity Relationship (QSAR) Analysis

The phenyl moiety of **IBR2** is situated in a spatially confined environment on RAD51 protein [15]. In this work, we have modified the indolyl and isoquinoline moieties of **IBR2** to further explore the structure-activity relationship. Our new IBR compounds described in this work covered the following structural diversity of interest: (1) different bioisosteres for replacing the indolyl ring, (2) chiral center of **IBR2** analogues, and (3) variable sizes of the central ring.

By modifying indole moiety to various bioisosteres, a potentially favorable modification site was identified. We found that compared with **IBR2**, **IBR123** and **124** showed more than 2-fold increase of activity; and both **IBR123** and **124** have included a potential hydrogen bond acceptor at the 7-position of the indolyl ring, suggesting further improvement could be made by utilizing this feature. Second, the growth inhibition assay results indicated that, compared with *S* isomers (average pIC₅₀ = 4.70), the *R* isomers (average pIC₅₀ = 4.96) are generally more active (Student's *t*-test, *p* = 0.0047) as summarized in Figure 3a. Moreover, increasing the central ring size from six to seven resulted in minimal change of activity of the *R* isomer (**IBR115**), but almost complete loss of function in the *S* isomer (**IBR116**). Interestingly, decreasing the central ring size from six to five resulted in more than 4-fold increase of activity (**IBR120**). If we assume that other confounding factors, such as assay variability, solubility differences, or variations in protein binding, remain similar among all the compound structures, these observed effects on activity could be viewed as results of certain

molecular recognition driven events. As we have discussed in previous sections, the docked conformation of **IBR120** indeed showed several favorable features of binding.

To better understand how these structural factors might have invoked such changes in activity, we decided to further look into the optimal docked conformations of all compounds. We hypothesized that the various sizes of the ring and substituents could result in differences in the optimal orientations of the indolyl, phenyl, and sulphonyl groups. This orientation can be readily quantified with a dihedral angle in the docking model (C-C-N-S, as shown in Figure 3b, inset). A cluster analysis (k-means, $k=2$) of this dihedral angle with regard to the IC_{50} 's indicated that the dihedral angles clustered around 75~100 degrees usually correlated with better activity; while the dihedral angles of -60~-110 degrees correlated with poorer activity (Figure 3b). Therefore the combined conformational effect elicited by the ring size and substituents determines the activity of a certain compound, at least in part.

We then attempted to build a predicative multivariate linear regression model based on the above observations obtained from all the synthesized chiral and racemic compounds. First, the molecules were divided into a test set (9 compounds) and a training set (16 compounds) using a random number generator to minimize potential bias. We then chose a handful of molecular descriptors (Molecular Weight, LogP, LogS, Polar Surface Area, Molecular Volume, Heat of Formation) to account for the difference in the physicochemical properties of the small molecules, and docking scores as indicators of overall binding capacity with RAD51. And we generated a first predicative model (Multiple R-squared: 0.77, Adjusted R-squared: 0.57, p-value: 0.039, see Figure S4 in Supporting Information). Next, based on the above exploratory analysis, we then included two extra parameters (dihedral angle and chirality) to account for the important conformational preference as we discussed above; and a much improved predicative model was obtained (Multiple R-squared: 0.98, Adjusted R-squared: 0.96, p-value: 0.0001, Figure 3c, Training Set). Using this model, we were able to predict the growth inhibition activity of most compounds in the test tests within 95% confidence interval (Figure 3d, Testing Set).

2.6 IBR120 inhibits RAD51 multimerization

On the RAD51 core domain, a hydrophobic pocket formed between β -strand B3 and α -helix A4 of RAD51 [24] is critical for RAD51 multimerization, which is also responsible for **IBR2** competitive binding [15]. Therefore, analogous IBR compounds were expected to inhibit RAD51 multimerization. To demonstrate that **IBR120** can indeed do this, we compared the gel filtration profile of RAD51 multimerization in the presence of **IBR120** or vehicle (DMSO) alone. In the presence of **IBR120**, the RAD51 elution profile exhibited a major peak consistent with the molecular weight of a monomer, while in the absence of **IBR120**, the majority of RAD51 formed multimers (Figure 4), indicating that **IBR120**, similar to **IBR2**, can inhibit RAD51 multimerization.

2.7 IBR120 inhibits Homologous Recombination (HR) repair

Inhibition of RAD51 function will lead to failure in HR repair. To test this possibility, we used an I-SceI inducible gene conversion assay that measures the DNA double strand break

repair frequency by detecting successful restoration of a fluorescent GFP from the repair substrate DR-GFP [15, 25]. DR-GFP, consisting of two nonfluorescent GFP derivatives, SceGFP and iGFP, was first stably integrated into HeLa cells. Upon I-SceI expression by transient transfection for 24 hours to induce DSBs, cells were treated with DMSO, 10 or 20 μ M of **IBR120** or **IBR2** for another 24 hours and the GFP positive population resulting from successful recombination was measured by flow cytometry. As shown in Figure 5, the HR frequency was significantly reduced after **IBR120** treatment in a dose dependent manner. Compared with **IBR2** treatment, **IBR120** treatment consistently led to greater depression of HR repair activity.

3. Conclusion

In summary, we have developed several stereoselective synthetic routes to synthesize chiral IBR2 analogues. One route featured the addition of N-Boc-3-bromo-indole **1**, 3-bromoindazole **5** and N-Boc-2-amino-5-bromothiazole **17** to the benzylidene sulfinamide **2** provided the separable diastereoisomers in medium to good yields. The biological assays and QSAR studies clearly demonstrated that *R* configuration exhibited improved bioactivity than *S* configuration, and the 5-membered central ring system proves to be the most active; these effects can be structurally correlated to the fine-tuning of the orientation of the two aromatic groups. As a result, these modifications led to more than 4-fold increase of growth inhibition activity in a panel of cancer cells, providing a significant milestone towards better RAD51 inhibitors.

Our synthetic scheme for most of the described IBR compounds relies on the stereoselective arylation of chiral benzylidene sulfinamide **2**, using *in situ* generated lithium reagent, followed by separation of diastereomers, removal of chiral auxiliary group, and further modifications thereafter. This route calls for a total of 6~10 steps of conversions to obtain the target molecules, in which a chromatographic separation of diastereomers is indispensable. These undesirable hurdles can be overcome in further optimization of the synthetic route. Indeed, in our synthesis of **IBR120**, we have employed catalytic stereoselective arylation methods to satisfactorily obtain the chiral starting material **24**, as previously described [17, 18]. We have then improved the oxidation/reduction [20] and ring closure reactions to achieve moderate to high yields of the desired enantiomers. It is noteworthy that these steps were performed under very mild conditions, and could be telescoped with some adjustments, which is a very attractive feature of this synthetic route. With further optimization, next generation of **IBR120** analogues can be synthesized and screened for improved activity.

We have previously shown that **IBR2** directly target RAD51 both *in vitro* and in cells [15]. In this work, we demonstrate that **IBR120** can disrupt RAD51 multimer formation *in vitro*, and inhibit HR repair in cells, leading to growth inhibition and cell death. Our results indicate that **IBR120** has similar biochemical and cellular consequences as **IBR2**, and suggest they may share an identical molecular target. Notably, the central ring structure in **IBR120** is only one carbon smaller than that in **IBR2**, and this structural similarity suggests they might share similar pharmacokinetic and pharmacodynamic properties as well, which awaits further in-depth studies *in vivo*. With the quantitative structure-activity analysis in

this work, further modifications are possible and necessary for this type of molecules to become clinically useful in the future.

IBR120 showed consistent potency in various cancer cell lines with different cancer origins and genotypes, suggesting **IBR120** is an effective anti-cancer agent that might be used for various types of tumors. Taken together, we expect further improvement can be achieved based on these findings and may lead to the discovery and development of novel pharmaceutical strategies against difficult-to-treat cancers.

4. Experimental Protocols

4.1 Cell lines and antibodies

Human leukemia cell line K562 and human breast cancer cell line T47D were maintained in RPMI 1640 (Invitrogen) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. Human breast cancer cell lines MCF7, MDA-MB-231, MDA-MB-361, MDA-MB-435, MDA-MB468, Hs578-T, human osteosarcoma cell line U20S, human glioblastoma cell line T98G and human cervical adenocarcinoma cell line HeLa were maintained in low glucose Dulbecco Modified Eagle Medium (DMEM, Invitrogen) supplemented with 10% FBS and 1% penicillin-streptomycin. Human normal mammary epithelial cell line MCF10A was maintained in DMEM/F12 (50:50) medium (Invitrogen) supplemented with 5% horse serum, 20 ng/mL of epidermal growth factor, 0.5 mg/mL of hydrocortisone, 100 ng/mL of Cholera Toxin, 10 µg/mL of insulin, and 1% penicillin-streptomycin. To establish HeLa cells that stably expressed DR-GFP construct, cells were transfected with DR-GFP plasmid and selected with 2 µg/mL puromycin. Antibody sources were: mouse anti-RAD51 clone 14B4 and mouse anti-p84 (GeneTex), and secondary antibodies conjugated with Horseradish Peroxidase (GeneTex).

4.2 Cell killing assay

Standard XTT assays with a four-day drug treatment procedure were performed to measure the dose dependent cytotoxicity of IBR analogs in cultured cells. In brief, cells were plated on 96-well dishes one day before the drug treatment, followed by drug treatment on day 2 and XTT assay on day 6 after drug addition by using a commercial cell proliferation kit (Roche Scientific) following the instructions. Triplicate sets were measured and compiled for final data presentation.

4.3 Homologous Recombination Assay

As previously described [15], HeLa cells stably expressing DR-GFP were transfected with the I-Sce expression vector pCBASce and treated with compounds or DMSO. Cells were then trypsinized and subjected to flow cytometry. GFP positive cell percentages from three independent experiments were summarized as means±SD.

4.4 Molecular Modeling

The molecular docking was carried out following a previously established protocol [15]. RAD51 coordinates were from PDB (Accession No: 1N0W). RAD51 residues containing atoms within 5Å distance from the BRC4 peptide in 1N0W was designated as binding site

for docking, including residues M158, Y159, I160, F167, P168, L171, S183, V185, L186, D187, N188, V189, A190, Y191, A192, R193, A194, F195, H199, Q202, L203, L204, Y205, Q206, A207, S208, A209, M210, V212, E213, Y216, L219, R247, R250, M251, L252, R254, L255, E258, F259. Structures of small molecules were generated and optimized and molecular docking was performed using ICM Pro (Molsoft), following standard procedures as described by the software manual, using default docking parameters at thoroughness = 5. Docked conformations with RMSD < 2 Å were considered acceptable and kept for future analysis. Dihedral angles in the lowest energy docked conformation were recorded. Statistic analysis, clustering analysis, and predictive multivariate linear model building was performed using R (Version 3.1.0).

4.5 Multimer Formation Assay

Multimer formation assay was performed following a previously established protocol [15]. A mixture of RAD51 (3.2 µg) and IBR120 (1:10 molar ratio) was incubated for 15 min at 37°C, supplemented with buffer (50mM triethanolamine-HCl [pH7.5], 0.5mM Mg(OAc)₂, 1mM DTT, 2mM ATP and 100 µg/ml BSA, total volume 20 µl) and incubated for 15min. The mixture was loaded onto a 2.4 ml Superdex 200 PC 3.2/30 column (Pharmacia) equilibrated with the same buffer as previously described[15]. Fractions (50 µl) were collected and 0.5 µl of each fraction was blotted onto PVDF membrane. RAD51 was detected using anti-RAD51 antibody (mAb 14B4, GeneTex).

4.6 Synthesis of IBR derivatives

4.6.1 Material and Methods—All reagents were used as received from commercial sources, unless specified otherwise, or prepared as described in the literature. Reactions requiring anhydrous conditions were performed in vacuum heat-dried glassware under nitrogen atmosphere. Reaction mixtures were stirred magnetically. DMF, dichloromethane and pyridine were distilled from CaH₂. ¹H NMR spectra were recorded at either 400 MHz or 500 MHz. ¹³C NMR spectra were recorded at either 125 MHz or 100 MHz. Chemical shifts (δ) are reported in ppm, and coupling constants (*J*) are in Hz. The following abbreviations were used to explain the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet.

4.6.2 (R)-2-Methylpropane-2-sulfinic acid [[2-(2-benzyloxy-ethyl)phenyl]-(1H-indazol-3-yl)-methyl]amide (6)—The solution of compound **5** (1.34 g, 6.85 mmol) in THF (40 mL) was cooled to -78 °C and *n*-BuLi (1.6 M in hexane, 4.28 mL, 6.95 mmol) was added dropwise. The resultant solution was stirred at -78 °C for 5 min. After that, *t*-BuLi (1.7 M in pentane, 8.06 mL, 13.70 mmol) was added dropwise and the resultant solution was stirred for 15 min at -78 °C. Then, a solution of compound **2**[17] (2.35 g, 6.85 mmol) in THF (8 mL) was added dropwise. The mixture was stirred for 1h at -78 °C before saturated aqueous NH₄Cl (3 mL) was added to quench the reaction. After the mixture was warmed up to room temperature, the mixture was poured to H₂O (200 mL) and extracted with CH₂Cl₂ (3 × 60 mL). The combined organic phases were dried over anhydrous Na₂SO₄. The solvent was removed in vacuo and the resultant residue was purified by silica gel chromatography (hexane / EtOAc / NH₃ = 100 : 50 : 1) to give compound **6** (1.36 g, 43%) as a yellow foam. ¹H NMR (500 MHz, CDCl₃) δ 7.43 (d, *J* = 8.0 Hz, 0.17H), 7.37–7.33 (m, 1.83H),

7.31–7.23 (m, 8H), 7.17–7.06 (m, 2H), 6.91 (t, $J = 8.8$ Hz, 0.83H), 6.83 (d, $J = 9.0$ Hz, 0.17H), 6.78 (t, $J = 7.5$ Hz, 0.17H), 6.73 (t, $J = 8.0$ Hz, 0.83H), 6.36 (d, $J = 6.5$ Hz, 0.83H), 6.24 (d, $J = 2.5$ Hz, 0.17H), 6.00 (d, $J = 6.5$ Hz, 1H), 4.48 (s, 1.66H), 4.28–4.22 (m, 0.34H), 3.78–3.69 (m, 1.66H), 3.46–3.41 (m, 0.34H), 3.33–3.23 (m, 1.66H), 3.20–3.07 (m, 0.34H), 1.29 (s, 1.5H), 1.27 (s, 7.5H); ^{13}C NMR (125 MHz, CDCl_3) δ 144.9, 144.9, 141.5, 141.5, 139.5, 138.5, 138.4, 138.1, 136.5, 130.9, 130.3, 128.8, 128.5, 128.5, 128.4, 128.0, 127.8, 127.7, 127.7, 127.5, 126.9, 126.8, 126.5, 126.4, 120.9, 120.9, 120.5, 120.5, 120.4, 120.3, 110.7, 110.7, 73.2, 72.9, 71.1, 70.7, 56.9, 56.6, 54.5, 54.4, 33.0, 32.8, 23.4, 23.0; MS (ESI) m/z 484 ($\text{M} + \text{Na}^+$); HRMS Calcd for $\text{C}_{27}\text{H}_{31}\text{N}_3\text{O}_2\text{SNa}$ ($\text{M} + \text{Na}^+$), 484.2035 Found: 484.2021.

4.6.3 3-[(S)-[2-(2-Benzyloxyethyl)phenyl]-((R)-2-methylpropane-2-sulfinylamino)methyl]indazole-1-carboxylic acid tert-butyl ester (7) and 3-[(R)-[2-(2-Benzyloxyethyl)phenyl]-((R)-2-methylpropane-2-

sulfinylamino)methyl]indazole-1-carboxylic acid tert-butyl ester (8)—To a 0 °C solution of compound **6** (706 mg, 1.53 mmol) in CH_2Cl_2 (20 mL) was added DMAP (5.0 mg, 0.04 mmol) followed by a solution of Boc_2O (350 mg, 1.60 mmol) in CH_2Cl_2 (2.0 mL). The mixture was warmed up to room temperature and stirred for 1h. Removal of all the solvent in vacuo resulted in a residue, which was purified by silica gel chromatography (hexane / EtOAc = 3 : 1 to 2 : 1) to give compound **8** (less polar, 117 mg, 14%) as an oil and compound **7** (more polar, 565 mg, 66%) as an oil.

Compound **7**: $[\alpha]_{\text{D}}^{20} = +7.3$ (c 0.9 CH_2Cl_2); ^1H NMR (500 MHz, CDCl_3) δ 8.13 (d, $J = 9.0$ Hz, 1H), 7.50 (d, $J = 8.0$ Hz, 1H), 7.44 (t, $J = 8.0$ Hz, 1H), 7.33–7.19 (m, 8H), 7.15–7.10 (m, 2H), 6.42 (d, $J = 3.0$ Hz, 1H), 4.54–4.48 (m, 2H), 4.28 (d, $J = 3.0$ Hz, 1H), 3.86–3.76 (m, 2H), 3.27 (t, $J = 6.5$ Hz, 2H), 1.70 (s, 9H), 1.25 (s, 9H); ^{13}C NMR (125 MHz, CDCl_3) δ 150.9, 149.4, 141.2, 138.4, 138.2, 138.0, 130.8, 128.9, 128.7, 128.7, 128.5, 127.7, 127.6, 127.0, 124.3, 123.4, 121.7, 114.9, 84.7, 73.1, 70.9, 56.5, 54.1, 32.5, 28.4, 23.0; MS (ESI) m/z 584 ($\text{M} + \text{Na}^+$); HRMS Calcd for $\text{C}_{32}\text{H}_{39}\text{N}_3\text{O}_4\text{SNa}$ ($\text{M} + \text{Na}^+$), 584.2559 Found: 584.2560.

Compound **8**: $[\alpha]_{\text{D}}^{20} = -112$ (c 1.1 CH_2Cl_2); ^1H NMR (500 MHz, CDCl_3) δ 8.07 (d, $J = 8.0$ Hz, 1H), 7.39 (dd, $J = 18.5, 7.5$ Hz, 2H), 7.32–7.17 (m, 9H), 7.02–6.96 (m, 2H), 6.26 (d, $J = 2.5$ Hz, 1H), 4.44–4.36 (m, 2H), 3.69–3.61 (m, 2H), 3.29–3.23 (m, 1H), 3.16–3.10 (m, 1H), 1.71 (s, 9H), 1.25 (s, 9H); ^{13}C NMR (125 MHz, CDCl_3) δ 150.8, 149.2, 141.2, 138.5, 138.4, 137.4, 130.8, 130.3, 129.0, 128.7, 128.5, 127.7, 127.6, 127.1, 123.8, 123.6, 121.2, 114.8, 84.8, 73.1, 70.9, 56.1, 53.4, 33.0, 28.4, 22.9; MS (ESI) m/z 584 ($\text{M} + \text{Na}^+$); HRMS Calcd for $\text{C}_{32}\text{H}_{39}\text{N}_3\text{O}_4\text{SNa}$ ($\text{M} + \text{Na}^+$), 584.2559 Found: 584.2559.

4.6.4 3-[(R)-Amino-[2-(2-benzyloxyethyl)phenyl]methyl]indazole-1-carboxylic acid tert-butyl ester (9)—To a solution of compound **8** (118 mg, 0.21 mmol) in MeOH (2.5 mL) was added 4M HCl solution (in dioxane, 2.5 mL). After the mixture was stirred at room temperature for 30 min, the mixture was diluted with H_2O (100 mL) and saturated aqueous NaHCO_3 (20 mL) was added. Then, the resultant aqueous solution was extracted with CH_2Cl_2 (3 \times 30 mL). The combined organic layers were washed with brine, and then dried over anhydrous Na_2SO_4 . After filtration and removal of the solvent in vacuo, the

residue was purified by silica gel column chromatography ($\text{CH}_2\text{Cl}_2 / \text{MeOH} / \text{NH}_3 = 200 : 10 : 1$) to afford compound **9** (87 mg, 90%) as a clear oil. $[\alpha]_{\text{D}}^{20} = -85$ (*c* 1.0 CH_2Cl_2); ^1H NMR (500 MHz, CDCl_3) δ 8.03 (d, *J* = 9.5 Hz, 1H), 7.41 (t, *J* = 7.3 Hz, 1H), 7.28–7.21 (m, 8H), 7.15–7.10 (m, 2H), 7.03 (t, *J* = 7.5 Hz, 1H), 5.89 (s, 1H), 4.51 (s, 2H), 3.78 (t, *J* = 8.0 Hz, 2H), 3.22 (t, *J* = 6.5 Hz, 2H), 2.98 (br, 2H), 1.73 (s, 9H); ^{13}C NMR (125 MHz, CDCl_3) δ 154.0, 149.5, 140.9, 140.4, 138.3, 137.6, 130.6, 128.9, 128.6, 128.2, 128.0, 127.9, 127.8, 127.1, 124.1, 123.4, 121.5, 114.7, 85.0, 73.2, 71.3, 51.1, 33.1, 28.4; MS (ESI) *m/z* 480 (*M* + Na^+); HRMS Calcd for $\text{C}_{28}\text{H}_{32}\text{N}_3\text{O}_3$ (*M* + H^+), 458.2444 Found: 458.2424.

4.6.5 3-[(R)-Benzyloxycarbonylamino-[2-(2-hydroxyethyl)phenyl]methyl]indazole-1-carboxylic acid tert-butyl ester (**10**)—

To a stirred solution of **9** (86 mg, 0.19 mmol) in MeOH (8 mL) was added 4M HCl in dioxane (0.4 mL), followed by Pd / C (50 mg, 10% Pd). The mixture was hydrogenated at room temperature under 1 atm for 1h. Then, the mixture was filtrated and the filtrate was neutralized with a NaHCO_3 aqueous solution. The resulted mixture was extracted with CH_2Cl_2 (3 \times 30 mL). The combined organic layers were washed with brine, and then dried over anhydrous Na_2SO_4 . After filtration and removal of the solvent in vacuo, the residue was solved in CH_2Cl_2 (3 mL) and the solvent was cooled to 0°C. To this solvent was added DIPEA (40 μL , 0.23 mmol) followed by CbzCl (40 mg, 0.23 mmol) dropwise. The mixture was stirred at 0°C for 20min. Then, all the solvent was removed in vacuo and the residue was purified by silica gel chromatography (hexane / EtOAc = 2 : 1) to give the compound **10** (57 mg, 61%) as a oil. $[\alpha]_{\text{D}}^{20} = -95$ (*c* 0.9 CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 8.04 (d, *J* = 8.4 Hz, 1H), 7.44 (ddd, *J* = 8.4, 7.2, 4.2 Hz, 1H), 7.33–7.22 (m, 9H), 7.16–7.11 (m, 2H), 6.66 (d, *J* = 7.6 Hz, 1H), 6.55 (d, *J* = 6.4 Hz, 1H), 5.14–5.05 (m, 2H), 3.97 (br, 2H), 3.31–3.25 (m, 1H), 3.22–3.16 (m, 1H), 2.77 (br, 1H), 1.72 (s, 9H); ^{13}C NMR (125 MHz, CDCl_3) δ 156.1, 150.6, 149.2, 140.9, 138.2, 137.6, 136.4, 130.7, 129.2, 128.7, 128.7, 128.6, 128.3, 128.2, 127.3, 123.8, 123.8, 120.8, 114.9, 85.3, 67.3, 63.8, 50.6, 35.9, 28.4; MS (ESI) *m/z* 524 (*M* + Na^+); HRMS Calcd for $\text{C}_{29}\text{H}_{31}\text{N}_3\text{O}_5\text{Na}$ (*M* + H^+), 524.2161 Found: 524.2156.

4.6.6 3-[(R)-Benzyloxycarbonylamino-[2-(2-methanesulfonyloxyethyl)phenyl]methyl]indazole-1-carboxylic acid tert-butyl ester (**11**)—

The compound **10** (57 mg, 0.11 mmol) was dissolved in CH_2Cl_2 (3 mL) and DIPEA (40 μL , 0.23 mmol) were added. Then, MsCl (13 μL , 0.17 mmol) was added dropwise. The mixture was stirred at room temperature for 20 min. After that, the solvent was removed in vacuo and the residue was purified by silica gel column chromatography (hexane / EtOAc = 2 : 1) to afford **11** (60 mg, 91%) as a white foam. $[\alpha]_{\text{D}}^{20} = -88$ (*c* 0.8 CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 8.06 (d, *J* = 8.4 Hz, 1H), 7.47 (ddd, *J* = 8.4, 7.2, 1.2 Hz, 1H), 7.34–7.26 (m, 9H), 7.22–7.15 (m, 2H), 6.54 (d, *J* = 7.2 Hz, 1H), 6.41 (d, *J* = 6.8 Hz, 1H), 5.15–5.07 (m, 2H), 5.48–4.43 (m, 2H), 3.39 (s, 2H), 2.84 (s, 3H), 1.73 (s, 9H); ^{13}C NMR (125 MHz, CDCl_3) δ 155.9, 150.1, 149.1, 140.9, 138.2, 136.4, 134.6, 131.0, 129.4, 129.2, 128.7, 128.7, 128.3, 128.2, 128.0, 124.0, 123.6, 120.7, 115.0, 85.5, 70.2, 67.3, 50.8, 37.3, 32.2, 28.4; MS (ESI) *m/z* 602 (*M* + Na^+); HRMS Calcd for $\text{C}_{30}\text{H}_{33}\text{N}_3\text{O}_7\text{SNa}$ (*M* + Na^+), 602.1937 Found: 602.1948.

4.6.7 (R)-3-(1,2,3,4-Tetrahydro-isoquinolin-1-yl)indazole-1-carboxylic acid tert-butyl ester (12)—To a solution of compound **11** (60 mg, 0.10 mmol) in MeOH (4 mL) was added Pd / C (55 mg, 10% Pd). The mixture was hydrogenated at room temperature under 1 atm for 1 h. Then, the solvent was removed in vacuo and the residue was purified by silica gel column chromatography (CH₂Cl₂ / MeOH / NH₃ = 150 : 10 : 1) to afford **12** (34 mg, 94%) as a foam. $[\alpha]_D^{20} = +106$ (c 1.0 CH₂Cl₂); ¹H NMR (500 MHz, CDCl₃) δ 8.06 (d, *J* = 9.0 Hz, 1H), 7.41 (ddd, *J* = 7.5, 7.5, 0.8 Hz, 1H), 7.22–7.15 (m, 3H), 7.08 (dd, *J* = 7.8, 7.5 Hz, 1H), 6.99 (t, *J* = 7.5 Hz, 1H), 6.86 (d, *J* = 8.0 Hz, 1H), 5.68 (s, 1H), 3.41–3.36 (m, 1H), 3.24–3.16 (m, 2H), 2.91–2.86 (m, 1H), 2.21 (br, 1H), 1.75 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 153.9, 149.6, 141.1, 135.4, 135.3, 129.4, 128.8, 127.8, 127.0, 126.2, 124.2, 123.5, 122.5, 114.8, 85.2, 56.4, 43.3, 30.0, 28.5; MS (ESI) *m/z* 372 (M + Na⁺); HRMS Calcd for C₂₁H₂₃N₃O₂Na (M + Na⁺), 372.1688 Found: 372.1687.

4.6.8 (R)-1-(1H-Indazol-3-yl)-2-phenylmethanesulfonyl-1,2,3,4-tetrahydro-isoquinoline (IBR117)—To a solution of compound **12** (34 mg, 0.097 mmol) in MeOH (1 mL) was added a solution of NaOMe (2.7 mg, 0.05 mmol) in MeOH (0.1 mL). The resultant mixture was stirred at room temperature for 3h. CH₂Cl₂ (20 mL) and H₂O (50 mL) were added to dilute the mixture and the aqueous phase was extracted with CH₂Cl₂ (3 × 25 mL). The combined organic layers were dried over anhydrous Na₂SO₄. Removal of all the solvent in vacuo gave a residue, which was dissolved in CH₂Cl₂ (1 mL). The resultant solution was cooled to 0°C and DIPEA (22 μL, 0.13 mmol) was added. Then, a solution of BnSO₂Cl (20 mg, 0.10 mmol) in CH₂Cl₂ (0.25 mL) was added dropwise. The mixture was stirred at 0°C for 20min. Removal of all the solvent gave a residue, which was purified by silica gel chromatography (hexane / EtOAc = 2 : 1) to afford compound **IBR117** (24 mg, 61%) as a white foam. $[\alpha]_D^{20} = +93$ (c 0.6 CH₂Cl₂); ¹H NMR (500 MHz, CDCl₃) δ 10.43 (br, 1H), 7.56 (dd, *J* = 8.3, 3.5 Hz, 1H), 7.50 (d, *J* = 8.5 Hz, 1H), 7.40 (t, *J* = 7.5 Hz, 1H), 7.26–7.10 (m, 5H), 7.07 (t, *J* = 7.5 Hz, 2H), 6.97 (d, *J* = 8.0 Hz, 1H), 6.79 (d, *J* = 7.5 Hz, 2H), 6.63 (s, 1H), 4.07–3.97 (m, 2H), 3.52 (dd, *J* = 14.0, 6.5 Hz, 1H), 3.28 (ddd, *J* = 12.5, 12.0, 3.5 Hz, 1H), 3.02 (ddd, *J* = 17.0, 11.5, 6.0 Hz, 1H), 2.77 (dd, *J* = 17.0, 2.5 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 146.7, 141.3, 134.1, 133.9, 130.7, 129.5, 128.8, 128.5, 128.5, 128.2, 127.6, 127.4, 126.6, 122.1, 121.8, 121.0, 110.2, 59.4, 53.2, 40.8, 29.1; MS (ESI) *m/z* 426 (M + Na⁺); HRMS Calcd for C₂₃H₂₂N₃O₂S (M + H⁺), 404.1433 Found: 404.1430.

4.6.9 3-[(S)-Amino-[2-(2-benzyloxyethyl)phenyl]methyl] indazole-1-carboxylic acid tert-butyl ester (13)—Compound **13** (203 mg, 91%) was prepared as a clear oil using the same conditions as described for the compound **9**. $[\alpha]_D^{20} = +85$ (c 1.0 CH₂Cl₂); ¹H NMR (500 MHz, CDCl₃) δ 8.03 (d, *J* = 8.5 Hz, 1H), 7.41 (t, *J* = 9.5 Hz, 1H), 7.30–7.20 (m, 8H), 7.16–7.10 (m, 2H), 7.03 (t, *J* = 7.5 Hz, 1H), 5.89 (s, 1H), 4.51 (s, 2H), 3.78 (t, *J* = 7.3 Hz, 2H), 3.22 (t, *J* = 7.0 Hz, 2H), 2.99 (br, 2H), 1.73 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 154.0, 149.5, 140.9, 140.4, 138.3, 137.6, 130.6, 128.9, 128.5, 128.2, 128.0, 127.9, 127.8, 127.1, 124.1, 123.4, 121.5, 114.7, 85.0, 73.2, 71.3, 51.1, 33.1, 28.4; MS (ESI) *m/z* 458 (M + H⁺); HRMS Calcd for C₂₈H₃₂N₃O₃ (M + H⁺), 458.2444 Found: 458.2435.

4.6.10 3-[(S)-Benzyloxycarbonylamino-[2-(2-hydroxyethyl)phenyl]methyl]indazole-1-carboxylic acid tert-butyl ester (14)—

Compound **14** (159 mg, 71%) was prepared as a white foam using the same conditions as described for the compound **10**. $[\alpha]_{\text{D}}^{20} = +99$ (*c* 0.9 CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 8.04 (d, *J* = 8.4 Hz, 1H), 7.44 (ddd, *J* = 8.4, 7.2, 1.2 Hz, 1H), 7.33–7.22 (m, 9H), 7.16–7.11 (m, 2H), 6.65 (d, *J* = 7.2 Hz, 1H), 6.55 (d, *J* = 6.4 Hz, 1H), 5.14–5.05 (m, 2H), 3.96 (br, 2H), 3.31–3.25 (m, 1H), 3.22–3.15 (m, 1H), 2.77 (br, 1H), 1.72 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 156.1, 150.6, 149.2, 140.9, 138.2, 137.6, 136.4, 130.7, 129.2, 128.7, 128.7, 128.6, 128.3, 128.2, 127.3, 123.8, 123.8, 120.8, 114.9, 85.3, 67.3, 63.8, 50.7, 35.9, 28.4; MS (ESI) *m/z* 524 (M + Na⁺); HRMS Calcd for C₂₉H₃₁N₃O₅Na (M + Na⁺), 524.2161 Found: 524.2169.

4.6.11 3-[(S)-Benzyloxycarbonylamino-[2-(2-methanesulfonyloxyethyl)phenyl]methyl]indazole-1-carboxylic acid tert-butyl ester (15)—

Compound **15** (161 mg, 88%) was prepared as a white foam using the same conditions as described for the compound **11**. $[\alpha]_{\text{D}}^{20} = +86$ (*c* 1.2 CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 8.06 (d, *J* = 8.4 Hz, 1H), 7.47 (ddd, *J* = 8.4, 7.2, 0.8 Hz, 1H), 7.34–7.26 (m, 9H), 7.22–7.15 (m, 2H), 6.54 (d, *J* = 7.2 Hz, 1H), 6.41 (d, *J* = 5.6 Hz, 1H), 5.15–5.07 (m, 2H), 5.57–4.43 (m, 2H), 3.39 (s, 2H), 2.84 (s, 3H), 1.73 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 155.9, 150.1, 149.2, 140.9, 138.2, 136.4, 134.6, 131.0, 129.4, 129.2, 128.7, 128.7, 128.3, 128.2, 128.0, 124.0, 123.6, 120.7, 115.0, 85.4, 70.1, 67.3, 50.8, 37.3, 32.2, 28.4; MS (ESI) *m/z* 602 (M + Na⁺); HRMS Calcd for C₃₀H₃₃N₃O₇SNa (M + Na⁺), 602.1937 Found: 602.1941.

4.6.12 (S)-3-(1,2,3,4-Tetrahydro-isoquinolin-1-yl)indazole-1-carboxylic acid tert-butyl ester (16)—

Compound **16** (95 mg, 97%) was prepared as a white foam using the same conditions as described for the compound **12**. $[\alpha]_{\text{D}}^{20} = -108$ (*c* 0.7 CH₂Cl₂); ¹H NMR (500 MHz, CDCl₃) δ 8.06 (d, *J* = 8.5 Hz, 1H), 7.41 (ddd, *J* = 7.5, 7.3, 0.8 Hz, 1H), 7.22–7.15 (m, 3H), 7.07 (t, *J* = 7.5 Hz, 1H), 6.99 (t, *J* = 4.0 Hz, 1H), 6.86 (d, *J* = 8.0 Hz, 1H), 5.68 (s, 1H), 3.41–3.36 (m, 1H), 3.24–3.16 (m, 2H), 2.91–2.86 (m, 1H), 2.21 (br, 1H), 1.75 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 153.9, 149.5, 141.1, 135.4, 135.3, 129.4, 128.8, 127.7, 127.0, 126.1, 124.2, 123.5, 122.5, 114.8, 85.2, 56.4, 43.3, 29.9, 28.5; MS (ESI) *m/z* 350 (M + H⁺); HRMS Calcd for C₂₁H₂₄N₃O₂ (M + H⁺), 350.1869 Found: 350.1863.

4.6.13 (S)-1-(1H-Indazol-3-yl)-2-phenylmethanesulfonyl-1,2,3,4-tetrahydro-isoquinoline (IBR118)—

IBR118 (73 mg, 67%) was prepared as white foam using the same conditions as described for the compound **IBR117**. $[\alpha]_{\text{D}}^{20} = -90$ (*c* 0.8 CH₂Cl₂); ¹H NMR (500 MHz, CDCl₃) δ 10.43 (br, 1H), 7.55 (dd, *J* = 8.0, 3.0 Hz, 1H), 7.50 (d, *J* = 8.5 Hz, 1H), 7.40 (t, *J* = 7.0 Hz, 1H), 7.26–7.10 (m, 5H), 7.06 (t, *J* = 7.0 Hz, 2H), 6.97 (d, *J* = 8.0 Hz, 1H), 6.79 (d, *J* = 7.5 Hz, 2H), 6.63 (s, 1H), 4.07–3.97 (m, 2H), 3.53 (dd, *J* = 12.5, 6.5 Hz, 1H), 3.28 (ddd, *J* = 12.5, 12.0, 3.5 Hz, 1H), 3.02 (ddd, *J* = 18.0, 11.5, 6.0 Hz, 1H), 2.77 (dd, *J* = 17.0, 3.0 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 146.7, 141.3, 134.1, 140.0, 130.7, 129.5, 128.8, 128.5, 128.5, 128.2, 127.6, 127.4, 126.6, 122.1, 121.8, 121.0, 110.2, 59.4, 53.2, 40.8, 29.1; MS (ESI) *m/z* 426 (M + Na⁺); HRMS Calcd for C₂₃H₂₁N₃O₂SNa (M + Na⁺), 426.1252 Found: 426.1252.

4.6.14 [5-[(R)-[2-(2-Benzyloxyethyl)phenyl]-((R)-2-methylpropane-2-sulfinylamino)methyl]thiazol-2-yl]carbamic acid tert-butyl ester (18) and [5-[(S)-[2-(2-Benzyloxyethyl)phenyl]-((R)-2-methylpropane-2-sulfinylamino)methyl] thiazol-2-yl]carbamic acid tert-butyl ester (19)—A

solution of compound **17** (390 mg, 1.40 mmol) in THF (8 mL) was cooled to $-78\text{ }^{\circ}\text{C}$ and *n*-BuLi (2.86 M, 1.22 mL, 3.50 mmol) was added slowly. The resultant mixture was stirred at $-78\text{ }^{\circ}\text{C}$ for 20min. After that, a solution of compound **2** (480 mg, 1.40 mmol) in THF (4 mL) was added slowly. The mixture was stirred at $-78\text{ }^{\circ}\text{C}$ for 20min. Saturated aqueous NH_4Cl (5 mL) was added to quench the reaction and the mixture was warmed up to room temperature. H_2O (50 mL) was added and the mixture was extracted with CH_2Cl_2 (3×30 mL). The combined organic phases were dried over anhydrous Na_2SO_4 . Removal of the solvent in vacuo resulted in a residue, which was purified by silica gel chromatography (hexane / EtOAc / $\text{NH}_3 = 100 / 200 / 0.6$ to $100 / 200 / 3$) to give compound **19** (less polar, 235 mg, 31%) as a foam and compound **18** (more polar, 60 mg, 7.9%) as a foam.

Compound **18**: $[\alpha]_{\text{D}}^{20} = -55.8$ (*c* 0.88 CH_2Cl_2); $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 11.73 (s, 1H), 7.60 (d, *J* = 8.0 Hz, 1H), 7.30–7.18 (m, 8H), 7.15 (s, 1H), 6.12 (d, *J* = 2.5 Hz, 1H), 4.53–4.46 (m, 2H), 3.81 (d, *J* = 2.5 Hz, 1H), 3.73–3.68 (m, 1H), 3.66–3.61 (m, 1H), 3.08–2.95 (m, 2H), 1.49 (s, 9H), 1.22 (s, 9H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 162.3, 153.0, 138.5, 138.5, 137.0, 135.1, 133.3, 130.8, 128.5, 128.3, 127.8, 127.8, 127.6, 127.2, 82.4, 73.2, 70.7, 56.2, 51.9, 33.2, 28.4, 22.9; MS (ESI) *m/z* 566 ($\text{M} + \text{Na}^+$); HRMS Calcd for $\text{C}_{28}\text{H}_{37}\text{N}_3\text{O}_4\text{S}_2\text{Na}$ ($\text{M} + \text{Na}^+$), 566.2123 Found: 566.2122.

Compound **19**: $[\alpha]_{\text{D}}^{20} = +3.5$ (*c* 0.83 CH_2Cl_2); $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.52 (d, *J* = 7.0 Hz, 1H), 7.29–7.18 (m, 9H), 7.11 (s, 1H), 6.06 (s, 1H), 4.49 (s, 2H), 4.00 (br, 1H), 3.68–3.60 (m, 2H), 3.02 (t, *J* = 6.5 Hz, 2H), 1.47 (s, 9H), 1.24 (s, 9H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 162.6, 152.8, 139.6, 138.3, 136.7, 132.8, 130.7, 128.6, 128.5, 127.8, 127.7, 127.5, 127.1, 82.5, 73.2, 70.6, 56.3, 52.9, 32.9, 28.4, 23.0; MS (ESI) *m/z* 566 ($\text{M} + \text{Na}^+$); HRMS Calcd for $\text{C}_{28}\text{H}_{37}\text{N}_3\text{O}_4\text{S}_2\text{Na}$ ($\text{M} + \text{Na}^+$), 566.2123 Found: 566.2128.

4.6.15 (5-[(S)-Amino-[2-(2-benzyloxyethyl)phenyl]methyl]thiazol-2-yl)carbamic acid tert-butyl ester (20)—A solution of compound **19** (219 mg, 0.40 mmol) in MeOH

(5 mL) was added 4 M HCl in dioxane (5 mL). The mixture was stirred at room temperature for 30 min. After that, the mixture was poured to an aqueous NaHCO_3 (2.0 g in 50 mL H_2O). The mixture was extracted with CH_2Cl_2 (3×30 mL). The combined organic phases were dried over anhydrous Na_2SO_4 . Removal of the solvent in vacuo resulted in a residue, which was purified by silica gel chromatography (CH_2Cl_2 / MeOH / $\text{NH}_3 = 200 / 20 / 1$) to afford compound **20** (178 mg, quant.) as an oil. $[\alpha]_{\text{D}}^{20} = +49.3$ (*c* 0.94 CH_2Cl_2); $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.51 (d, *J* = 7.5 Hz, 1H), 7.31–7.17 (m, 8H), 6.90 (s, 1H), 5.59 (s, 1H), 4.47 (s, 2H), 3.67–3.59 (m, 3H), 3.07–3.01 (m, 1H), 2.94–2.88 (m, 1H), 2.26 (br, 2H), 1.43 (s, 9H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 161.6, 153.0, 142.4, 138.3, 136.6, 136.2, 133.7, 130.3, 128.6, 127.8, 127.8, 127.8, 127.3, 126.6, 81.9, 73.3, 71.2, 49.7, 33.1, 28.4; MS (ESI) *m/z* 462 ($\text{M} + \text{Na}^+$); HRMS Calcd for $\text{C}_{24}\text{H}_{29}\text{N}_3\text{O}_3\text{SNa}$ ($\text{M} + \text{Na}^+$), 462.1827 Found: 462.1828.

4.6.16 (5-[(S)-[2-(2-Benzyloxyethyl)phenyl]phenylmethanesulfonylamino-methyl]thiazol-2-yl)carbamic acid tert-butyl ester (21)—A solution of compound **20** (178 mg, 0.40 mmol) in CH₂Cl₂ (8 mL) was added DIPEA (116 μL, 0.65 mmol) and DMAP (8.0 mg, 0.066 mmol) at 0 °C. Then, a solution of BnSO₂Cl (130 mg, 0.68 mmol) was added dropwise. The mixture was warmed up to room temperature and stirred for 20 min. Removal of the solvent in vacuo resulted in a residue, which was purified by silica gel chromatography (hexane / EtOAc = 2 / 1) to give compound **21** (232 mg, 97%) as a yellow oil. $[\alpha]_D^{20} = -33.6$ (c 1.26 CH₂Cl₂); ¹H NMR (500 MHz, CDCl₃) δ 12.06 (s, 1H), 7.35 (td, *J* = 7.5, 1.5 Hz, 1H), 7.28–7.22 (m, 7H), 7.19–7.14 (m, 4H), 7.05 (s, 1H), 7.00 (d, *J* = 7.0 Hz, 2H), 6.77 (br, 1H), 5.84 (d, *J* = 8.0 Hz, 1H), 4.20–4.11 (m, 2H), 3.99 (s, 2H), 3.64 (dt, *J* = 9.0, 4.5 Hz, 1H), 3.48 (ddd, *J* = 9.5, 9.5, 4.5 Hz, 1H), 2.91 (ddd, *J* = 14.5, 9.3, 4.5 Hz, 1H), 2.67 (dt, *J* = 14.5, 5.0 Hz, 1H), 1.46 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 162.2, 153.0, 138.7, 138.3, 137.5, 135.1, 133.8, 132.8, 131.5, 131.1, 129.2, 129.1, 128.9, 128.7, 128.6, 128.2, 128.0, 127.3, 82.2, 73.1, 70.7, 59.9, 55.3, 33.1, 28.4; MS (ESI) *m/z* 616 (M + Na⁺); HRMS Calcd for C₃₁H₃₅N₃O₅S₂Na (M + Na⁺), 616.1916 Found: 616.1909.

4.6.17 (5-[(S)-[2-(2-Hydroxyethyl)phenyl]phenylmethanesulfonylamino-methyl]thiazol-2-yl)-carbamic acid tert-butyl ester (22)—To a solution of compound **21** (225 mg, 0.38 mmol) in MeOH (10 mL) was added Pd / C (10% Pd, 198 mg) and 4 M HCl in dioxane (0.5 mL). The mixture was hydrogenated (1 atm) for 5 h. The mixture was subjected to filtration and the filtrate was poured to H₂O (50 mL). Saturated aqueous NaHCO₃ (10 mL) was added and the mixture was extracted with CH₂Cl₂ (3 × 25 mL). The combined organic phases were dried over anhydrous Na₂SO₄. Removal of the solvent in vacuo resulted in a residue, which was purified by silica gel chromatography (CH₂Cl₂ / MeOH = 15 / 1) to afford compound **22** (152 mg, 80%) as a foam. $[\alpha]_D^{20} = -41$ (c 0.58 CH₂Cl₂); ¹H NMR (500 MHz, CDCl₃) δ 7.37 (t, *J* = 7.0 Hz, 2H), 7.32–7.24 (m, 4H), 7.20 (t, *J* = 7.5 Hz, 2H), 7.03 (d, *J* = 7.5 Hz, 2H), 6.97 (s, 1H), 6.50 (br, 1H), 5.96 (d, *J* = 8.5 Hz, 1H), 4.21 (d, *J* = 14.0 Hz, 1H), 4.07 (d, *J* = 13.5 Hz, 1H), 3.80 (dt, *J* = 9.5, 5.0 Hz, 1H), 3.71–3.65 (m, 1H), 2.81 (ddd, *J* = 14.0, 9.3, 5.5 Hz, 1H), 2.68 (dt, *J* = 14.5, 5.0 Hz, 1H), 1.46 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 162.0, 152.8, 139.1, 137.9, 135.3, 133.3, 131.6, 131.1, 129.3, 129.1, 128.7, 128.6, 127.5, 82.5, 64.1, 60.0, 54.7, 35.4, 28.4; MS (ESI) *m/z* 526 (M + Na⁺); HRMS Calcd for C₂₄H₂₉N₃O₅S₂Na (M + Na⁺), 526.1447 Found: 526.1442.

4.6.18 [5-((S)-2-Phenylmethanesulfonyl-1,2,3,4-tetrahydroisoquinolin-1-yl)thiazol-2-yl]carbamic acid tert-butyl ester (23)—To a solution of compound **22** (152 mg, 0.30 mmol) in CH₂Cl₂ (5 mL) was added DMAP (3.0 mg, 0.025 mmol) and DIPEA (63 μL, 0.36 mmol) at 0 °C. Then, MsCl (80 μL, 1.03 mmol) was added dropwise. The mixture was stirred at room temperature for 20 min. After that, the solvent was removed in vacuo to afford a residue, which was purified by gel chromatography (CH₂Cl₂ / MeOH = 30 / 1) to give a foam (168 mg). The yielded foam (168 mg) was dissolved in THF (10 mL) and the solution was cooled to 0 °C. To this solution was added KHMDS (0.5 M in toluene, 1.15 mL, 0.58 mmol) and the mixture was stirred at 0 °C for 5 min. The reaction was quenched with aqueous saturated NH₄Cl (5 mL) and H₂O (30 mL) was added. The mixture was extracted with CH₂Cl₂ (3 × 25 mL) and the combined organic phases were dried over

anhydrous Na₂SO₄. The solvent was removed in vacuo and the resultant residue was purified by silica gel chromatography (hexane / EtOAc = 2 / 1) to give compound **23** (118 mg, 81%) as a foam. $[\alpha]_D^{20} = -50.7$ (c 0.63 CH₂Cl₂); ¹H NMR (500 MHz, CDCl₃) δ 11.92 (s, 1H), 7.27–7.24 (m, 1H), 7.21–7.17 (m, 3H), 7.14–7.09 (m, 5H), 6.97 (d, *J* = 7.0 Hz, 1H), 6.08 (s, 1H), 4.13–4.08 (m, 2H), 3.63 (dd, *J* = 14.0, 6.0 Hz, 1H), 3.29 (ddd, *J* = 15.5, 10.5, 3.0 Hz, 1H), 2.82 (ddd, *J* = 16.5, 12.0, 5.0 Hz, 1H), 2.67 (dt, *J* = 15.0, 3.0 Hz, 1H), 1.47 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 162.5, 152.9, 136.8, 134.0, 133.5, 132.4, 130.9, 129.5, 128.8, 128.7, 128.7, 128.2, 127.9, 126.6, 82.4, 59.6, 53.4, 39.9, 29.9, 28.5; MS (ESI) *m/z* 508 (M + Na⁺); HRMS Calcd for C₂₄H₂₇N₃O₄S₂Na (M + Na⁺), 508.1341 Found: 508.1344.

4.6.19 5-((S)-2-Phenylmethanesulfonyl-1,2,3,4-tetrahydro-isoquinolin-1-yl)thiazol-2-ylamine (IBR119)—To a solution of compound **23** (106 mg, 0.22 mmol) in CH₂Cl₂ (10 mL) was added TFA (1 mL) at 0 °C. The mixture was warmed up to room temperature and stirred for 5h. CH₂Cl₂ (20 mL) and H₂O (30 mL) were added to the reaction mixture. The reaction was quenched with aqueous saturated NH₄Cl (5 mL) and H₂O (30 mL) was added. After saturated aqueous NaHCO₃ (10 ml) was added, the mixture was extracted with CH₂Cl₂ (3 × 20 mL) and the combined organic phases were dried over anhydrous Na₂SO₄. The solvent was removed in vacuo and the resultant residue was purified by silica gel chromatography (hexane / EtOAc / NH₃ = 1 : 1 : 0 to 1 : 2 : 0.005) to give compound **IBR119** (73 mg, 87%) as a foam. $[\alpha]_D^{20} = -62.9$ (c 0.43 CH₂Cl₂); ¹H NMR (500 MHz, CDCl₃) δ 7.19–7.26 (m, 1H), 7.24–7.19 (m, 3H), 7.16–7.10 (m, 4H), 6.98 (d, *J* = 8.0 Hz, 1H), 6.61 (s, 1H), 5.93 (s, 1H), 5.07 (br, 2H), 4.19–4.10 (m, 2H), 3.62 (dd, *J* = 14.3, 6.0 Hz, 1H), 3.22 (ddd, *J* = 15.5, 10.5, 3.5 Hz, 1H), 2.78 (ddd, *J* = 17.8, 11.3, 5.0 Hz, 1H), 2.66 (dd, *J* = 16.5, 1.5 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 169.1, 138.9, 133.8, 133.6, 130.9, 129.4, 129.3, 128.8, 128.7, 128.7, 128.3, 127.9, 126.5, 59.8, 53.7, 39.6, 29.9; MS (ESI) *m/z* 386 (M + H⁺); HRMS Calcd for C₁₉H₂₀N₃O₂S₂ (M + H⁺), 386.0997 Found: 386.0996.

4.6.20 (R)-N-((2-(hydroxymethyl)phenyl)(1H-indol-3-yl)methyl)-1-phenylmethanesulfonamide (25)—To a solution of compound **24** [17] (176 mg, 0.44 mmol) in dioxane-water (3:1, 8 mL) were added 2, 6-lutidine (0.101 mL, 0.88 mmol), OsO₄ (2.5% in tert-butanol, 89 μL, 8.8 μmol) and NaIO₄ (371.4 mg, 1.75 mmol). The reaction was stirred at r.t and monitored by TLC. After the reaction was complete, water (10 mL) and CH₂Cl₂ (20 mL) were added. The organic layer was separated, and the water layer was extracted by CH₂Cl₂ (10 mL × 3). The combined organic layers were washed with brine and dried over Na₂SO₄. The solvent was removed under reduced pressure. The residue was absorbed onto SiO₂, and eluted with EtOAc/hexane (1:3) to afford the aldehyde intermediate as white foam (158 mg). This foam was dissolved in THF-MeOH (1:1, 4 mL) at 0°C and NaBH₄ (44 mg, 1.17 mmol) in THF (1 mL) was added. The reaction was stirred for 10 min at room temperature and saturated aqueous NH₄Cl (3 mL) was added to quench the reaction. H₂O (30 mL) was added and the mixture was extracted with Et₂O (3 × 20 mL). The combined organic phases were dried with anhydrous Na₂SO₄. The solvent was removed under reduced pressure and the residue was absorbed onto silica gel and eluted with hexane / EtOAc (1 : 2) to give compound **25** (146 mg, 82%) as a foam. $[\alpha]_D^{20} = +70.2$ (c 1.06 CH₂Cl₂); ¹H NMR (400 MHz, CD₂Cl₂) δ 8.26 (s, 1H), 7.62 (d, *J* = 7.5 Hz, 1H), 7.36–7.52

(m, 6H), 7.15–7.31 (m, 4H), 7.02–7.04 (d, $J = 7.5$ Hz, 2 H), 6.94 (s, 1H), 6.27 (d, $J = 7.5$ Hz, 1H), 5.76 (d, $J = 7.8$ Hz, 1H), 4.47–4.57 (m, 2H), 4.13 (d, $J = 13.8$ Hz, 1H), 4.02 (d, $J = 13.8$ Hz, 1H), 1.80 (t, $J = 6.0$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 140.1, 138.2, 136.9, 130.9, 130.7, 129.1, 129.0, 128.9, 128.7, 128.6, 128.6, 128.6, 125.5, 123.8, 122.6, 120.1, 119.6, 116.0, 111.6, 63.3, 60.1, 53.8; MS (ESI) m/z 429 ($\text{M} + \text{Na}^+$); HRMS Calcd for $\text{C}_{23}\text{H}_{22}\text{N}_2\text{O}_3\text{SNa}$ ($\text{M} + \text{Na}^+$), 429.1249 Found: 429.1230.

4.6.21 (R)-3-(2-(benzylsulfonyl)isoindolin-1-yl)-1H-indole (IBR120)—To a stirred solution of compound **25** (28 mg, 0.069 mmol) in CH_2Cl_2 (2.0 mL) was added Et_3N (9.6 μL , 0.069 mmol) at 0°C . Then, MsCl (7.1 μL , 0.092 mmol) was added dropwise. The mixture was warmed up to room temperature and stirred for 1h. The reaction solution was diluted with CH_2Cl_2 (5 ml) and washed with ice water. Organic phases were dried with anhydrous Na_2SO_4 and removed under vacuum. The residue was then dissolved in dry MeCN (2 mL) and to this solution was added DIPEA dropwise at 0°C . The reaction was allowed warm up to r.t and monitored by TLC. After the reaction was completed, saturated aqueous NH_4Cl (1 mL) was added and the mixture was extracted with CH_2Cl_2 (3×5 mL). The combined organic phases were dried over anhydrous Na_2SO_4 . Removal of the solvent in vacuo resulted in a residue, which was purified by silica gel chromatography ($\text{EtOAc} / \text{hexane} = 1 : 3$) to give compound **IBR120** (14.2 mg, 53 %) as a white solid. $[\alpha]_{\text{D}}^{20} = +89.5$ (c 0.44 CH_2Cl_2); ^1H NMR (400 MHz, CD_2Cl_2) δ 8.40 (s, 1H), 7.37–7.42 (m, 2H), 7.31–7.37 (t, $J = 7.3$ Hz, 1H), 7.21–7.30 (m, 3H), 7.13–7.19 (m, 3H), 7.03–7.07 (d, $J = 7.6$ Hz, 1H), 6.85–6.97 (m, 4H), 6.41 (d, $J = 1.8$ Hz, 1H), 4.86 (d, $J = 13.3$ Hz, 1H), 4.38–4.42 (dd, $J = 2.8, 13.6$ Hz, 1H), 3.75 (d, $J = 13.6$ Hz, 1H), 3.64 (d, $J = 13.7$ Hz, 1H); ^{13}C NMR (125MHz, CD_2Cl_2) δ 140.7, 137.4, 136.5, 131.2, 129.7, 128.8, 128.7, 128.5, 128.4, 125.9, 125.7, 124.0, 122.9, 122.8, 120.4, 120.1, 116.0, 112.1, 63.2, 59.5, 54.2; MS (ESI) m/z 411 ($\text{M} + \text{Na}^+$); HRMS Calcd for $\text{C}_{23}\text{H}_{20}\text{N}_2\text{O}_2\text{SNa}$ ($\text{M} + \text{Na}^+$), 411.1143 Found: 411.1134.

4.6.22 (S)-3-(2-(benzylsulfonyl)isoindolin-1-yl)-1H-indole (IBR121)—**IBR121** (13.6 mg, 51 %) was prepared as white solid using the same conditions as described for the compound **IBR120**. $[\alpha]_{\text{D}}^{20} = -90.1$ (c 0.75 CH_2Cl_2); ^1H NMR (400 MHz, CD_2Cl_2) δ 8.37 (s, 1H), 7.39–7.42 (m, 2H), 7.32–7.35 (m, 1H), 7.22–7.28 (m, 3H), 7.13–7.17 (m, 3H), 7.03–7.05 (d, $J = 7.7$ Hz, 1H), 6.85–6.96 (m, 4H), 6.41 (s, 1H), 4.85 (d, $J = 13.3$ Hz, 1H), 4.37 (d, $J = 13.8$ Hz, 1H), 3.74 (d, $J = 13.5$ Hz, 1H), 3.63 (d, $J = 13.6$ Hz, 1H); ^{13}C NMR (125MHz, CD_2Cl_2) δ 140.7, 137.3, 136.4, 131.2, 129.7, 128.7, 128.7, 128.4, 128.4, 125.7, 124.0, 122.9, 122.8, 120.4, 120.1, 116.0, 112.1, 63.1, 59.5, 54.2; MS (ESI) m/z 411 ($\text{M} + \text{Na}^+$); HRMS Calcd for $\text{C}_{23}\text{H}_{20}\text{N}_2\text{O}_2\text{SNa}$ ($\text{M} + \text{Na}^+$), 411.1143 Found: 411.1150.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgement

This work is supported by NIH grant to W.-H. Lee (CA107568). We thank the UCI Molecular Modeling Facility for technical support.

Appendix A. Supplementary data

Supporting information related to this article can be found online. Supporting information contains: (A) Cyclization Conditions; (B) Raw dataset for QSAR analysis; (C) Chiral HPLC analysis; (D) Initial Predictive Multivariate Linear Model; (E) NMR spectra.

Abbreviations

| | |
|-------------|--|
| DMAP | 4,4-dimethylaminopyridine |
| XTT | sodium 3'-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro-)benzene sulfonate |
| IBR | RAD51 inhibitor |










Reference



1. Carvalho JF, Kanaar R. Targeting homologous recombination-mediated DNA repair in cancer. *Expert Opinion on Therapeutic Targets*. 2014; 18:427–458. [PubMed: 24491188]
2. Guo XE, Ngo B, Modrek AS, Lee W-H. Targeting Tumor Suppressor Networks for Cancer Therapeutics. *Current Drug Targets*. 2014; 15:2–16. [PubMed: 24387338]
3. Ward A, Khanna KK, Wiegans AP. Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51. *Cancer Treatment Reviews*. 2014; 41:35–45. [PubMed: 25467108]
4. Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. *Nature Reviews Cancer*. 2012; 12:801–817.
5. Flygare J, Fält S, Ottervald J, Castro J, Dackland Å-L, Hellgren D, Wennborg A. Effects of HsRad51 Overexpression on Cell Proliferation, Cell Cycle Progression, and Apoptosis. *Exp. Cell Res*. 2001; 268:61–69. [PubMed: 11461118]
6. Chen C-F, Chen P-L, Zhong Q, Sharp ZD, Lee W-H. Expression of BRC Repeats in Breast Cancer Cells Disrupts the BRCA2-Rad51 Complex and Leads to Radiation Hypersensitivity and Loss of G2/M Checkpoint Control. *J. Biol. Chem*. 1999; 274:32931–32935. [PubMed: 10551859]
7. Chen P-L, Chen C-F, Chen Y, Xiao J, Sharp ZD, Lee W-H. The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. *Proc. Natl. Acad. Sci. USA*. 1998; 95:5287–5292. [PubMed: 9560268]
8. Klein HL. The consequences of Rad51 overexpression for normal and tumor cells. *DNA Repair*. 2008; 7:686–693. [PubMed: 18243065]
9. Maacke H, Jost K, Opitz S, Miska S, Yuan Y, Hasselbach L, Luttes J, Kalthoff H, Sturtzbecher H-W. DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. *Oncogene*. 2000; 19:2791–2795. [PubMed: 10851081]
10. Qiao G-B, Wu Y-L, Yang X-N, Zhong W-Z, Xie D, Guan X-Y, Fischer D, Kolberg H-C, Kruger S, Stuerzbecher H-W. High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. *Br. J. Cancer*. 2005; 93:137–143. [PubMed: 15956972]
11. Raderschall E, Stout K, Freier S, Suckow V, Schweiger S, Haaf T. Elevated Levels of Rad51 Recombination Protein in Tumor Cells. *Cancer Res*. 2002; 62:219–225. [PubMed: 11782381]
12. Richardson C, Stark JM, Ommundsen M, Jasin M. Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability. *Oncogene*. 2004; 23:546–553. [PubMed: 14724582]
13. Robu ME, Inman RB, Cox MM. RecA protein promotes the regression of stalled replication forks in vitro. *Proc. Natl. Acad. Sci. USA*. 2001; 98:8211–8218. [PubMed: 11459955]


14. Slupianek A, Schmutte C, Tomblin G, Nieborowska-Skorska M, Hoser G, Nowicki MO, Pierce AJ, Fishel R, Skorski T. BCR/ABL Regulates Mammalian RecA Homologs, Resulting in Drug Resistance. *Mol. Cell.* 2001; 8:795–806. [PubMed: 11684015]
15. Zhu J, Zhou L, Wu G, Konig H, Lin X, Li G, Qiu X-L, Chen C-F, Hu C-M, Goldblatt E, Bhatia R, Chamberlin AR, Chen P-L, Lee W-H. A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia. *EMBO Molecular Medicine.* 2013; 5:1–13. [PubMed: 23283747]
16. Reddy, IK.; Mehvar, R. Chirality in Drug Design and Development. 1 edn. CRC Press; 2004.
17. Qiu X-L, Zhu J, Wu G, Lee W-H, Chamberlin AR. Stereoselective synthesis of chiral IBR2 analogues. *J. Org. Chem.* 2009; 74:2018–2027. [PubMed: 19191556]
18. Wang Y-Q, Song J, Hong R, Li H, Deng L. Asymmetric Friedel-Crafts Reaction of Indoles with Imines by an Organic Catalyst. *J. Am. Chem. Soc.* 2006; 128:8156–8157. [PubMed: 16787078]
19. Welch WM, Hanau CE, Whalen WM. A novel synthesis of 3-substituted indazole derivatives. *Synthesis.* 1992:937–939.
20. Yu W, Mei Y, Kang Y, Hua Z, Jin Z. Improved Procedure for the Oxidative Cleavage of Olefins by OsO₄/NaIO₄. *Org. Lett.* 2004; 6:3217–3219. [PubMed: 15355016]
21. Hudis CA, Gianni L. Triple-Negative Breast Cancer: An Unmet Medical Need. *The Oncologist.* 2011; 16:1–11. [PubMed: 21278435]
22. Peddi PF, Ellis MJ, Ma C. Molecular Basis of Triple Negative Breast Cancer and Implications for Therapy. *International Journal of Breast Cancer.* 2012; 2012:1–7.
23. ATCC Cell Lines - ATCC: The Global Bioresource Center. <http://www.atcc.org>
24. Pellegrini L, Yu DS, Lo T, Anand S, Lee M, Blundell TL, Venkitaraman AR. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. *Nature.* 2002; 420:287–293. [PubMed: 12442171]
25. Pierce AJ, Johnson RD, Thompson LH, Jasin M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. *Genes Dev.* 1999; 13:2633–2638. [PubMed: 10541549]


Highlights


- A class of novel indole alkaloid derivatives were synthesized.
- These compounds efficiently inhibit the growth of a panel of cancer cell lines.
- IBR120 shows 5-fold increase of activity on a triple-negative breast cancer cell line.
- IBR120 disrupts RAD51 multimerization, impairs homologous recombination, induces apoptosis.
- Structure activity relationship and molecular modeling studies were included.
































IBR2 analogues inhibit the growth of the triple-negative human breast cancer cell line MDA-MB-468.

Table 1

| Cmpd. | IC ₅₀ (mM) | Cmpd. | IC ₅₀ (mM) | Cmpd. | IC ₅₀ (mM) |
|---------------------|-----------------------|---------------------|-----------------------|-----------------------|-----------------------|
| IBR2 (<i>rac</i>) | 14.8 | | | | |
| IBR101 (<i>R</i>) | 11.7 | IBR109 (<i>R</i>) | 14.8 | IBR117 (<i>R</i>) | 9.5 |
| IBR102 (<i>S</i>) | 13.2 | IBR110 (<i>S</i>) | 16.7 | IBR118 (<i>S</i>) | 14.3 |
| IBR103 (<i>R</i>) | 12.7 | IBR111 (<i>R</i>) | 11.1 | IBR119 (<i>S</i>) | >25 |
| IBR104 (<i>S</i>) | 19.2 | IBR112 (<i>S</i>) | 22.2 | IBR120 (<i>R</i>) | 3.1 |
| IBR105 (<i>R</i>) | 14.2 | IBR113 (<i>R</i>) | 13.6 | IBR121 (<i>S</i>) | >12 |
| IBR106 (<i>S</i>) | 17.2 | IBR114 (<i>S</i>) | 20.7 | IBR122 (<i>rac</i>) | 12.7 |
| IBR107 (<i>R</i>) | 11.2 | IBR115 (<i>R</i>) | 14.7 | IBR123 (<i>rac</i>) | 6.3 |
| IBR108 (<i>S</i>) | 25.7 | IBR116 (<i>S</i>) | >50 | IBR124 (<i>rac</i>) | 6.2 |

Table 2Inhibition activity of **IBR120** on a panel of cancer cell lines.

| Cell line | Cell Type [23] | IC ₅₀ (μM) |
|------------|--|-----------------------|
| K562 | Chronic Myelogenous Leukemia | 3.6 ± 0.7 |
| MCF7 | Mammary Gland Adenocarcinoma | 3.1 ± 0.2 |
| MDA-MB-231 | Mammary Gland Adenocarcinoma | 3.5 ± 0.4 |
| MDA-MB-361 | Mammary Gland Adenocarcinoma | 4.5 ± 0.7 |
| MDA-MB-468 | Mammary Gland Adenocarcinoma | 3.1 ± 0.4 |
| MDA-MB-435 | Melanoma / Mammary Gland Ductal Carcinoma | 4.0 ± 0.7 |
| Hs578-T | Mammary Gland Carcinoma | 4.9 ± 1.0 |
| T47D | Mammary Gland Ductal Carcinoma | 6.3 ± 1.5 |
| U2OS | Osteosarcoma | 4.7 ± 0.5 |
| T98G | Glioblastoma Multiforme | 9.5 ± 0.9 |
| HeLa | Cervix Adenocarcinoma | 3.6 ± 0.6 |
| MCF10A | Mammary Gland, Normal epithelial cell line | > 30 |